Differences in nicotine intake and effects from electronic and combustible cigarettes among dual users.


Journal

Addiction (Abingdon, England)
ISSN: 1360-0443
Titre abrégé: Addiction
Pays: England
ID NLM: 9304118

Informations de publication

Date de publication:
04 2020
Historique:
received: 20 01 2019
revised: 23 05 2019
accepted: 29 10 2019
pubmed: 7 11 2019
medline: 18 2 2021
entrez: 7 11 2019
Statut: ppublish

Résumé

To describe systemic nicotine exposure and subjective effects of electronic cigarettes (e-cigarettes) in people who use both e-cigarettes and cigarettes (dual users), including within-subject comparisons of e-cigarette and cigarette use. Two-arm, counterbalanced cross-over study. Participants used their usual brand of e-cigarette or cigarette during a standardized session in a 2-week study. Hospital research ward, San Francisco, CA, USA. Thirty-six healthy (eight women, 28 men) participants. Plasma nicotine was analyzed by gas chromatography-tandem mass spectrometry; nicotine withdrawal, urge to smoke and vape, affective states, craving, satisfaction and psychological reward were measured by standardized questionnaires. Compared with cigarettes, average maximum plasma nicotine concentration (C Systemic nicotine exposure was, on average, lower with single use of e-cigarettes compared with cigarettes, and e-cigarettes were judged to be less satisfying and rewarding and reduced craving less than cigarettes.

Identifiants

pubmed: 31691397
doi: 10.1111/add.14884
pmc: PMC7339816
mid: NIHMS1057729
doi:

Substances chimiques

Nicotine 6M3C89ZY6R

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

757-767

Subventions

Organisme : NCRR NIH HHS
ID : UL1 RR024131
Pays : United States
Organisme : NIDA NIH HHS
ID : P30 DA012393
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA039264
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA180890
Pays : United States
Organisme : NHLBI NIH HHS
ID : U54 HL147127
Pays : United States

Informations de copyright

© 2020 Society for the Study of Addiction.

Références

Nicotine Tob Res. 2001 Feb;3(1):7-16
pubmed: 11260806
Drug Alcohol Depend. 2017 Jan 01;170:93-101
pubmed: 27883949
Tob Regul Sci. 2016 Oct;2(4):352-362
pubmed: 27942543
Arch Gen Psychiatry. 1986 Mar;43(3):289-94
pubmed: 3954551
Psychopharmacology (Berl). 2016 Aug;233(15-16):2933-41
pubmed: 27235016
Drug Alcohol Depend. 2017 Sep 1;178:391-398
pubmed: 28704768
Psychopharmacology (Berl). 2006 Aug;187(3):385-96
pubmed: 16752139
Cancer Epidemiol Biomarkers Prev. 2003 May;12(5):468-71
pubmed: 12750245
Addiction. 2015 Aug;110(8):1352-6
pubmed: 25996087
Tob Regul Sci. 2016 Oct;2(4):363-376
pubmed: 28393086
Pharmacol Rev. 2005 Mar;57(1):79-115
pubmed: 15734728
Psychopharmacology (Berl). 2017 Mar;234(5):773-779
pubmed: 28070620
Regul Toxicol Pharmacol. 2018 Dec;100:25-34
pubmed: 30201538
Tob Control. 2016 Apr;25(e1):e6-9
pubmed: 26324250
Int J Healthc Med Sci. 2018 Jun;4(6):111-116
pubmed: 30450441
Tob Control. 2019 Jan;28(1):13-19
pubmed: 29419488
Biol Mass Spectrom. 1991 May;20(5):247-52
pubmed: 1883864
Drug Alcohol Depend. 2018 Aug 01;189:42-48
pubmed: 29879680
Pharmacol Biochem Behav. 1999 Jan;62(1):165-72
pubmed: 9972860
Drug Alcohol Depend. 2019 Oct 1;203:83-87
pubmed: 31408770
J Consult Clin Psychol. 2018 May;86(5):486-491
pubmed: 29683704
Nebr Symp Motiv. 2009;55:143-69
pubmed: 19013943
Br J Addict. 1991 Sep;86(9):1119-27
pubmed: 1932883
Addiction. 2016 Mar;111(3):535-44
pubmed: 26430813
J Natl Cancer Inst. 2019 Oct 1;111(10):1078-1087
pubmed: 30657926
Nicotine Tob Res. 2015 Feb;17(2):142-9
pubmed: 25239957
Addiction. 2007 Feb;102(2):324-34
pubmed: 17222288
Nicotine Tob Res. 2017 Oct 1;19(10):1224-1231
pubmed: 27281605
Tob Control. 2017 Mar;26(e1):e23-e28
pubmed: 27729564
Nicotine Tob Res. 2019 Aug 19;21(9):1279-1284
pubmed: 30365010
Brain Res Brain Res Rev. 2005 Feb;48(1):74-97
pubmed: 15708629
Nicotine Tob Res. 2015 Feb;17(2):186-92
pubmed: 25332459
Addiction. 2020 Jun;115(6):1149-1159
pubmed: 31837232
JAMA Intern Med. 2019 Jun 1;179(6):777-785
pubmed: 31009023

Auteurs

Gideon St Helen (G)

Clinical Pharmacology Research Program, Division of Cardiology, Department of Medicine, University of California, San Francisco, CA, USA.
Center for Tobacco Control Research and Education, University of California, San Francisco, CA, USA.
Tobacco Center of Regulatory Science, University of California, San Francisco, CA, USA.

Natalie Nardone (N)

Clinical Pharmacology Research Program, Division of Cardiology, Department of Medicine, University of California, San Francisco, CA, USA.
Tobacco Center of Regulatory Science, University of California, San Francisco, CA, USA.

Newton Addo (N)

Clinical Pharmacology Research Program, Division of Cardiology, Department of Medicine, University of California, San Francisco, CA, USA.

Delia Dempsey (D)

Clinical Pharmacology Research Program, Division of Cardiology, Department of Medicine, University of California, San Francisco, CA, USA.

Christopher Havel (C)

Clinical Pharmacology Research Program, Division of Cardiology, Department of Medicine, University of California, San Francisco, CA, USA.

Peyton Jacob (P)

Clinical Pharmacology Research Program, Division of Cardiology, Department of Medicine, University of California, San Francisco, CA, USA.
Center for Tobacco Control Research and Education, University of California, San Francisco, CA, USA.
Tobacco Center of Regulatory Science, University of California, San Francisco, CA, USA.

Neal L Benowitz (NL)

Clinical Pharmacology Research Program, Division of Cardiology, Department of Medicine, University of California, San Francisco, CA, USA.
Center for Tobacco Control Research and Education, University of California, San Francisco, CA, USA.
Tobacco Center of Regulatory Science, University of California, San Francisco, CA, USA.
Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH